GILEAD | HIV

Working to end the epidemic.

HIV Pipeline*

Clinical Program	Indication	Phase		
HIV Prevention				
Lenacapavir (Purpose 1 & 2)	HIV PrEP LAI		NDA & EC approved	EC Approved
Lenacapavir (PURPOSE 365)	HIV PrEP LAI			
HIV Treatment				
Bictegravir/lenacapavir oral combination (ARTISTRY-1 & -2)	HIV Oral			
Islatravir/lenacapavir oral combination (ISLEND-1 &-2)[1]	HIV LAO			
HIV capsid inhibitor (GS-3107)	HIV LAI			
HIV Capsid inhibitor (WONDERS-1 & -2)	HIV LAO			
Lenacapavir + teropavimab + zinlirvimab	HIV LAI			Breakthrough Therapy Designation
HIV INSTI (GS-1219)	HIV LAI			
HIV INSTI (GS-3242)	HIV LAI			
HIV NRTTI (GS-1614)	HIV LAI			
HIV Cure				
Teropavimab + zinlirvimab[2,3]	HIV Cure			
Vesatolimod (FRESH)	HIV Cure			
HIV bispecific T-cell engager (GS-8588)	HIV Cure			

*As reported in Gilead's Q3 2025 Earnings Statement
Subject to Gilead and Merck co-development and co-commercialization agreement. 2. Teropavimab andzinlirvimab are broadly neutralizing antibody (bNAbs). 3. Non-Gilead sponsored trial(s) ongoing.
HIV – human immunodeficiency virus, INSTI – integrase strand transfer inhibitor, LAI – long-acting injectable, LAO – long-acting oral, NDA – new drug application, NRTTI - nucleoside reverse transcriptase translocation inhibitor, PrEP - pre-exposure prophylaxis, FPI – first patient in.